KRAS and neoplasm: Specifically we expressed different G12V-activated KRAS effector domain mutants (KRASV12, KRASV12/S35, KRASV12/G37, KRASV12/E38 or KRASV12/C40) [23], [24], [28]–[30] alone or in conjunction with induction of BrafV600E expression in BrafCA mice and assessed tumor formation and pathology.